Drupal.behaviors.print = function(context) {window.print();window.close();}>
Santaris Releases Phase II Data Showing Its HCV Drug Is Well Tolerated, Effective
October 06, 2011
Santaris Releases Phase II Data Showing Its HCV Drug Is Well Tolerated, Effective
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News
Santaris to Present Phase IIa Data on HCV Drug
April 19, 2012 / Gene Silencing News
Santaris Aims for Second Phase II Trial of HCV Drug, 'Comfortable' with IP Position
January 12, 2012 / Gene Silencing News
UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News
Santaris Presents Phase IIa Data on microRNA-Targeting HCV Drug
November 10, 2011 / Gene Silencing News